A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.
TP53 and FGFR3 mutations are the most common mutations in bladder cancers. FGFR3 mutations are most frequent in low-grade low-stage tumours, whereas TP53 mutations are most frequent in high-grade high-stage tumours. Several studies have reported FGFR3 and TP53 mutations to be mutually exclusive even...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/53f5b53e570340e18b559b078466bd8a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:53f5b53e570340e18b559b078466bd8a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:53f5b53e570340e18b559b078466bd8a2021-11-18T08:05:14ZA meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.1932-620310.1371/journal.pone.0048993https://doaj.org/article/53f5b53e570340e18b559b078466bd8a2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23272046/?tool=EBIhttps://doaj.org/toc/1932-6203TP53 and FGFR3 mutations are the most common mutations in bladder cancers. FGFR3 mutations are most frequent in low-grade low-stage tumours, whereas TP53 mutations are most frequent in high-grade high-stage tumours. Several studies have reported FGFR3 and TP53 mutations to be mutually exclusive events, whereas others have reported them to be independent. We carried out a meta-analysis of published findings for FGFR3 and TP53 mutations in bladder cancer (535 tumours, 6 publications) and additional unpublished data for 382 tumours. TP53 and FGFR3 mutations were not independent events for all tumours considered together (OR = 0.25 [0.18-0.37], p = 0.0001) or for pT1 tumours alone (OR = 0.47 [0.28-0.79], p = 0.0009). However, if the analysis was restricted to pTa tumours or to muscle-invasive tumours alone, FGFR3 and TP53 mutations were independent events (OR = 0.56 [0.23-1.36] (p = 0.12) and OR = 0.99 [0.37-2.7] (p = 0.35), respectively). After stratification of the tumours by stage and grade, no dependence was detected in the five tumour groups considered (pTaG1 and pTaG2 together, pTaG3, pT1G2, pT1G3, pT2-4). These differences in findings can be attributed to the putative existence of two different pathways of tumour progression in bladder cancer: the CIS pathway, in which FGFR3 mutations are rare, and the Ta pathway, in which FGFR3 mutations are frequent. TP53 mutations occur at the earliest stage of the CIS pathway, whereas they occur would much later in the Ta pathway, at the T1G3 or muscle-invasive stage.Yann NeuzilletXavier PaolettiSlah OuerhaniPierre Mongiat-ArtusHany SolimanHugues de TheMathilde SibonyYves DenouxVincent MolinieAurélie HeraultMay-Linda LepagePascale MailleAudrey RenouDimitri VordosClaude-Clément AbbouAshraf BakkarBernard AsselainNadia KourdaAmel El GaaiedKaren LeroyAgnès LaplancheSimone BenhamouThierry LebretYves AlloryFrançois RadvanyiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 12, p e48993 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Yann Neuzillet Xavier Paoletti Slah Ouerhani Pierre Mongiat-Artus Hany Soliman Hugues de The Mathilde Sibony Yves Denoux Vincent Molinie Aurélie Herault May-Linda Lepage Pascale Maille Audrey Renou Dimitri Vordos Claude-Clément Abbou Ashraf Bakkar Bernard Asselain Nadia Kourda Amel El Gaaied Karen Leroy Agnès Laplanche Simone Benhamou Thierry Lebret Yves Allory François Radvanyi A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. |
| description |
TP53 and FGFR3 mutations are the most common mutations in bladder cancers. FGFR3 mutations are most frequent in low-grade low-stage tumours, whereas TP53 mutations are most frequent in high-grade high-stage tumours. Several studies have reported FGFR3 and TP53 mutations to be mutually exclusive events, whereas others have reported them to be independent. We carried out a meta-analysis of published findings for FGFR3 and TP53 mutations in bladder cancer (535 tumours, 6 publications) and additional unpublished data for 382 tumours. TP53 and FGFR3 mutations were not independent events for all tumours considered together (OR = 0.25 [0.18-0.37], p = 0.0001) or for pT1 tumours alone (OR = 0.47 [0.28-0.79], p = 0.0009). However, if the analysis was restricted to pTa tumours or to muscle-invasive tumours alone, FGFR3 and TP53 mutations were independent events (OR = 0.56 [0.23-1.36] (p = 0.12) and OR = 0.99 [0.37-2.7] (p = 0.35), respectively). After stratification of the tumours by stage and grade, no dependence was detected in the five tumour groups considered (pTaG1 and pTaG2 together, pTaG3, pT1G2, pT1G3, pT2-4). These differences in findings can be attributed to the putative existence of two different pathways of tumour progression in bladder cancer: the CIS pathway, in which FGFR3 mutations are rare, and the Ta pathway, in which FGFR3 mutations are frequent. TP53 mutations occur at the earliest stage of the CIS pathway, whereas they occur would much later in the Ta pathway, at the T1G3 or muscle-invasive stage. |
| format |
article |
| author |
Yann Neuzillet Xavier Paoletti Slah Ouerhani Pierre Mongiat-Artus Hany Soliman Hugues de The Mathilde Sibony Yves Denoux Vincent Molinie Aurélie Herault May-Linda Lepage Pascale Maille Audrey Renou Dimitri Vordos Claude-Clément Abbou Ashraf Bakkar Bernard Asselain Nadia Kourda Amel El Gaaied Karen Leroy Agnès Laplanche Simone Benhamou Thierry Lebret Yves Allory François Radvanyi |
| author_facet |
Yann Neuzillet Xavier Paoletti Slah Ouerhani Pierre Mongiat-Artus Hany Soliman Hugues de The Mathilde Sibony Yves Denoux Vincent Molinie Aurélie Herault May-Linda Lepage Pascale Maille Audrey Renou Dimitri Vordos Claude-Clément Abbou Ashraf Bakkar Bernard Asselain Nadia Kourda Amel El Gaaied Karen Leroy Agnès Laplanche Simone Benhamou Thierry Lebret Yves Allory François Radvanyi |
| author_sort |
Yann Neuzillet |
| title |
A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. |
| title_short |
A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. |
| title_full |
A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. |
| title_fullStr |
A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. |
| title_full_unstemmed |
A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. |
| title_sort |
meta-analysis of the relationship between fgfr3 and tp53 mutations in bladder cancer. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/53f5b53e570340e18b559b078466bd8a |
| work_keys_str_mv |
AT yannneuzillet ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT xavierpaoletti ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT slahouerhani ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT pierremongiatartus ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT hanysoliman ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT huguesdethe ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT mathildesibony ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT yvesdenoux ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT vincentmolinie ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT aurelieherault ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT maylindalepage ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT pascalemaille ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT audreyrenou ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT dimitrivordos ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT claudeclementabbou ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT ashrafbakkar ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT bernardasselain ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT nadiakourda ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT amelelgaaied ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT karenleroy ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT agneslaplanche ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT simonebenhamou ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT thierrylebret ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT yvesallory ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT francoisradvanyi ametaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT yannneuzillet metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT xavierpaoletti metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT slahouerhani metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT pierremongiatartus metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT hanysoliman metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT huguesdethe metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT mathildesibony metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT yvesdenoux metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT vincentmolinie metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT aurelieherault metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT maylindalepage metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT pascalemaille metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT audreyrenou metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT dimitrivordos metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT claudeclementabbou metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT ashrafbakkar metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT bernardasselain metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT nadiakourda metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT amelelgaaied metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT karenleroy metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT agneslaplanche metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT simonebenhamou metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT thierrylebret metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT yvesallory metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer AT francoisradvanyi metaanalysisoftherelationshipbetweenfgfr3andtp53mutationsinbladdercancer |
| _version_ |
1718422227459768320 |